NCT03924414 · Phase 4 · ACTIVE NOT RECRUITING
Trial of Parkinson's And Zoledronic Acid
This trial is testing whether a single IV infusion of zoledronic acid, a bone-strengthening drug already approved for osteoporosis, can reduce fractures in people aged 60 and older who have Parkinson's disease or a related movement disorder. It is a Phase 4 trial, meaning the drug is already approved and researchers are now studying it in this specific patient population. It is home-based and includes about 2,650 participants across the U.S.
You may qualify if
- Men and women age 60 years or older
- Current Parkinson's Disease diagnosis or neurodegenerative parkinsonism diagnosis (including progressive supranuclear palsy, multiple system atrophy, cortical basal degeneration, vascular parkinsonism, dementia with Lewy bodies or another form of neurodegenerative parkinsonism) based on an expert assessment (neurologist diagnosis via medical records confirmation or Telemedicine Screening Assessment)
- Willing and able to continue in follow-up for at least 2 years
- Willing and able to provide informed consent
You're excluded if
- History of hip fracture
- Any use of a bisphosphonate drug within the last 12 months
- Use of any other osteoporosis treatment (such as SERMs and denosumab) within the last 6 months
- Tooth extraction or invasive dental procedures within the past 30 days or planned/scheduled extraction/procedure in the next 12 months
- Non-ambulatory, i.e., unable to walk without assistance of another person.
- Undergoing kidney dialysis
- A diagnosis of multiple myeloma or Paget's disease
- Unable to speak or read English sufficiently to complete informed consent
- Any other criteria, which would make the patient unsuitable to participate in this study as determined by the study staff (e.g., an uncontrolled drug and/or alcohol addiction)
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-03-04